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Abstract
The present study was carried out to assess the role of androgen receptor CAG repeat polymorphism and X chromosome
inactivation (XCI) pattern among Indian PCOS women and controls which has not been hitherto explored and also to test
the hypothesis that shorter CAG alleles would be preferentially activated in PCOS. CAG repeat polymorphism and X
chromosome methylation patterns were compared between PCOS and non-PCOS women. 250 PCOS women and 299
controls were included for this study. Androgen receptor CAG repeat sizes, XCI percentages, and clinical and biochemical
parameters were measured. The mean CAG repeat number is similar between the cases (18.7460.13) and controls
(18.7360.12). The obese PCOS women were significantly more frequent in the ,18 and .20 CAG repeat category than the
lean PCOS women, yielding a highly significant odds (p=0.001). Among the women with non-random X-inactivation, alleles
with ,19 repeats were more frequently activated among cases than controls (p=0.33). CAG repeat polymorphism by itself
cannot be considered as a useful marker for discriminating PCOS. We observed a trend of preferential activation of the
shorter allele among the PCOS cases with non random XCI pattern. In the obese PCOS women, this microsatellite variation
may account for the hyperandrogenicity to a larger extent than the lean PCOS women.
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Introduction
Polycystic Ovary Syndrome (PCOS), the leading cause of
anovulatory infertility among premenopausal women, is now
essentiallyknownasandrogenexcessdisorder[1].Itischaracterized
by three key features viz., hyperandrogenism, chronic anovulation
or infrequent ovulation and presence of numerous follicular cysts in
the enlarged ovaries. One of the mechanisms leading to the
spectrum of pathological conditions deals with the abnormal steroid
synthesis from ovaries and adrenals resulting in a hyperandrogenic
state. Consequently, an excess of androgens seems to interfere with
the process of follicularmaturation leadingto the PCOS phenotype.
At the molecular level, the effect of androgens is mediated through
the activation of androgen receptor (AR). The activity of AR is
modulatedbya polyglutamine tract of variable size inits N-terminal
transactivation domain. This polyglutamine tract is encoded by a
highly polymorphic CAG repeat sequence in exon 1 of the AR gene
located on the X-chromosome [2].
In vitro studies showed an inverse relation between number of
CAG repeats in the AR gene and AR activity [2], and a number of
clinical conditions have been attributed to the resulting variation
in androgen activity as listed by Mifsud et al. [3]. Thus, variation
in the length of the AR (CAG)n repeats may provide insights into
the underlying genetic etiology and further development of PCOS.
In view of this, a number of studies have tried to investigate the
role of CAG repeats of the AR gene in PCOS yielding contrasting
results. Nevertheless, some of these studies reported a trend for
shorter CAG alleles to be more frequent among PCOS cases than
the controls [4,5] which is consistent with the in vitro evidence of
the greater receptor activity of the shorter CAG alleles. Apart from
the microsatellite CAG repeat analysis, some of the studies have
also looked into the X-chromosome inactivation (XCI) patterns
among the cases and controls [4,6]. However, these studies are
largely restricted to the Caucasian populations. Neither the pattern
of association of CAG repeat polymorphism with the PCOS nor
the XCI patterns vis-a `-vis the CAG repeat number are studied
in any detail among the South-Asian women in general and
particularly from India.
It is well known that the process of rapid urbanization and
consequent lifestyle changes in India and other developing
countries is increasing the burden of many complex diseases like
PCOS, cardiovascular diseases and type-2 diabetes at an alarming
rate and it is imperative to explore the nature of genetic and
environmental etiology in the manifestation of such disorders
among them. We have, in a relatively large cohort of South Indian
women comprising of PCOS cases and healthy controls, investi-
gated the role of CAG repeat polymorphism in the manifestation
of PCOS and also studied the XCI pattern among them with the
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12401underlying hypothesis that shorter CAG repeat alleles would be
preferentially activated in the women with PCOS.
Results
CAG allele distribution
In our cohort of 250 PCOS women and 299 controls, the
androgen receptor CAG repeats ranged from 8–30 and 9–31,
respectively (Fig.1). The mean CAG repeat number is almost
identical between the cases (18.7460.13) and controls (18.736
0.12), while the median value is same (19 repeats) for both. The
allele distribution pattern was similar and not significantly different
between cases and the controls {x
2=29.8, degrees of freedom
(df)=22, p=0.122} (Fig.1). Both the cases and controls had a
greater frequency of the biallelic mean CAG repeat sizes in the
polymorphic range below the median value of 19 repeats. The
frequency distribution of the PCOS and control women bearing
repeat values below and above the median are presented in Table 1
and 2, separately for the total alleles (2N), biallelic mean, X-
weighted biallelic mean and for both longer and shorter alleles.
Contingency x
2 suggests homogeneity of distribution of cases and
controls in the three qualitative categories of the repeat values
(df=2, p$0.33), for each of the above allele categories.
Internal consistency in the CAG distribution patterns
Despite socioeconomic hierarchy and religious heterogeneity,
the populations of Andhra Pradesh were found to be genetically
homogenous [7]. Given that our sample consisted of sizeable
cohort of Muslim subjects, we repeated the above analysis for the
Hindu caste and Muslim subjects separately. But this categoriza-
tion does not seem to have any significant effect on the allele
distribution profiles (Table 3). Given that the Muslim and Hindu
cases were predominantly drawn from the Osmania General
Hospital and Anu Test Tube Baby Centre, respectively, and they
in turn also represent lower and higher socioeconomic status, the
results do not seem to suggest any effect of socioeconomic
hierarchy in the pattern of manifestation of PCOS in relation to
CAG repeats. Further, we drew 50, 60 & 70% random subset of
case and control samples and repeated the above analysis to test
for internal consistency in our data. Overall, the results suggest
that the distribution of CAG repeats is homogenous (results not
presented) between cases and controls in the entire polymorphic
range indicating internal consistency.
Logistic regression was performed on the entire cohort of cases
and controls to assess the association of repeat length (biallelic
mean) with PCOS taking age and BMI as covariates, but the result
was rather non-significant (OR=0.993, p=0.94). To examine if
there is any effect of repeat numbers in the extreme ends of the
allele spectrum on PCOS, odds ratio was also computed for two
groups, (i) #15 repeat size VS .15 and (ii) #22 repeat size
VS.22. Neither of the two analysis yielded any significant odds
{(i) OR=1.42, p=0.581 and (ii) OR=1.53, p=0.366}. Further,
even after merging the extremes of the two groups (i.e #15 and
.22), no significant odds could be obtained (OR=1.33, p=0.49).
This is a situation in which we are unable to reject null
hypotheses H0: h=0 {where, h=log(odds ratio)} against H1: h ?
0 (two-tailed alternative). We tried to estimate if our study with
given sample size is sufficiently powered to reject null hypothesis,
based on a previous study showing stronger association of shorter
CAG alleles with PCOS with an estimated effect size of 0.318 in
log of odds ratio [4]. Using G*Power software (version 3.1.0,
Germany) [8], and given this magnitude of effect size, our sample
has over 99% power to detect such an effect. We also estimated
the minimum effect size, with which our study would have
detected significant association (p=0.05) with 90% power, which
turns out to be 0.14. However, the effect size calculated from our
data for CAG biallelic mean is 0.01, which is close to zero and far
smaller than the minimum effect size estimated above to be able to
reject null hypothesis with sufficient power. Conversely, our study
can be considered as sufficiently powered in not rejecting the null
hypothesis.
The case cohort was also analyzed in two groups, based on body
mass index (BMI), i.e. lean PCOS (BMI,25) and obese PCOS
(BMI$25) cases (Fig.2). Given the lean body mass of Indian
women, we considered 25 to be the cut-off for distinguishing the
lean women from overweight/obese women albeit as per the
World Health Organisation (WHO) criteria, BMI .25 is con-
sidered overweight while BMI .30 is considered obese. While
there was no significant difference in the allele distribution pattern
when analyzed as separate cohorts, vis-a `-vis the controls, we found
Figure 1. Distribution of CAG alleles in PCOS cases and controls.
doi:10.1371/journal.pone.0012401.g001
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between the lean and obese PCOS cases (Fig.3a). Lean PCOS
cases had significantly higher frequency (64.5%) of biallelic mean
in the range of 18–20 than the obese cases (38.8%) (x
2 =10.37,
df=2, p=0.005). Conversely, the obese PCOS cases are found to
be more frequent on either side of the middle range of the CAG
repeats (,18 and .20). The significant difference between the
lean and obese PCOS cases becomes much more pronounced
when we consider both the extreme ranges of CAG repeats
merged together in contrast to the middle range (x
2 =10.37,
df=1, p=0.001) (Fig.3b). This is pertinent given the plausible
effect of CAG repeats in both the extremes in the androgen
production and metabolism which could finally lead to a state of
hyperandrogenism in a PCOS phenotype as demonstrated in
previous studies [4,6]. However, in comparison to controls, a
greater proportion of the obese PCOS cases are again found in the
CAG repeat range of ,18 and .20, though statistically non
significant (Fig.4). Similar analysis did not reveal any stratification
in the CAG repeat number among the controls in function of BMI
(p=0.364).
Given significant heterogeneity in the pattern of CAG biallelic
mean distribution of the obese and lean PCOS cases, odds were
also computed for the pooled range of CAG repeats on both sides
(,18 or .20) vis-a `-vis the middle range (18–20), considering the
pooled case cohort versus controls (Table 4) and the lean versus
obese PCOS cases (Table 5). While in the former case, significant
odds were not obtained at 5% level even after removing the effect
of age and BMI, a highly significant odds were obtained
(p=0.001) in the latter (after removing age effect) to suggest that
PCOS cases with repeat ranges ,18 and .20, had 3 times greater
risk to develop obesity and subsequent metabolic complications
associated with PCOS. This particular regression analysis yielding
highly significant odds ratio among the lean and obese PCOS
women (Table 5) was further considered for post-hoc power
analysis, specifying the odds ratio as 3.04, p-value as 0.05 and
sample size as 170 (total number of lean and obese PCOS cases) as
input parameters and with the conditional probability (under null
hypothesis) of PCOS subject being obese taken as 0.63 for the
patients with CAG repeat length of ,18 or .20. This analysis
yielded high power (1-b error probability) of 0.928, suggesting that
our inference based on logistic regression has sufficient statistical
power.
X chromosome inactivation (XCI) analysis
Analysis for X-chromosome inactivation revealed that majority
of the cohort (74% of the PCOS cases and 69% of the controls)
follow random (,60%) X-inactivation pattern with reference to
the CAG repeats (Fig.5). Nonrandom X-inactivation (60%–80%)
was observed only in 21% of the PCOS cases and 24% controls.
This difference in XCI pattern between cases and controls is
neither significant nor follow the expected trend of cases showing
relatively greater proportion of nonrandom inactivation. However,
among the subset of samples with non-random X-inactivation,
alleles with ,19 repeats were preferentially more activated among
the PCOS women (71%) as compared to the controls (63%),
though the difference was not statistically significant (p=0.33)
(Fig.6). Logistic regression analysis for preferential activation of
shorter alleles yielded an odds ratio of 1.443 though not significant
(p=0.33). With reference to the effect size {log(odds ratio)=
log(2)=0.318} obtained in the previous study [4], our sample of
133 individuals with non-randon X-Inactivation gives a power of
95.6%. With our sample size, the expected minimum effect size to
achieve significant association at 90% power is estimated to be
0.281.
X_weighted_biallelic mean was calculated by incorporating
XCI percentages and their distribution was similar to that of the
biallelic mean distribution (Table 1), which did not show any
difference between cases and controls, hence no perceptible
epigenetic influence. This analysis was also done separately for
Hindus and Muslims and for lean and obese PCOS cases, but the
results exhibited essentially the same trend of X-inactivation.
Logistic regression was also performed on the entire cohort of
cases and controls to assess the association of X-weighted biallelic
mean with PCOS taking age and BMI as covariates. The odds was
Table 1. Distribution (%) of PCOS cases and controls according to the qualitative categories of CAG repeats.
Total number of CAG alleles CAG Biallelic Mean CAG X-weighted Biallelic Mean
Repeat size Cases (2N=498) Controls (2N=592) Cases (N=249) Controls (N=296) Cases (N=249) Controls (N=296)
,19 43.7 45.6 47.7 47.9 38.9 41.5
19 17.2 14 9.2 9.4 14.4 14.8
.19 38.9 40.3 42.9 42.5 46.5 43.5
x2=2.18, df=2, p=0.336; x2=0.212, df=2, p=0.899; x2=0.513, df=2, p=0.773.
doi:10.1371/journal.pone.0012401.t001
Table 2. Distribution (%) of PCOS cases and controls according to the qualitative categories of shorter and longer CAG repeats
alleles.
(i) Shorter CAG alleles (ii) Longer CAG alleles
Repeat size Cases (N=249) Controls (N=296) Repeat size Cases (N=249) Controls (N=296)
,17 35.7 34.1 ,20 38.5 37.1
17 18.0 16.5 20 14.4 18.5
.17 46.2 49.3 .20 46.9 44.2
x2=0.561, df=2, p=0.755; x2=1.668, df=2, p=0.434.
doi:10.1371/journal.pone.0012401.t002
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analysis, the expected effect size is estimated to be 0.24 from the
earlier data [4], for which the power obtained with our sample was
close to 1 (0.99).
Clinical correlation
We obtained the testosterone (T) levels and hirsutism score of
the PCOS cases (Table 6) and found that the frequency of PCOS
women was not significantly different across the allele categories
with respect to T levels in the pooled sample. Independent analysis
of Hindu and Muslim samples resulted in the same pattern (results
not presented). However, 72% of the obese PCOS cases with
repeat length # 19 show high testosterone values as compared to
the lean PCOS with same range of CAG repeats (31%), although
this difference in the proportions do not reach statistical
significance (p=0.15). On the other hand, the clinical measure
of hyperandrogenism as reflected by hirsutism score, was found to
be significantly more frequent among the obese when compared to
the lean PCOS (x
2=9.9, df=1, p=0.002), in concurrence to the
highly significant correlation observed between hirsutism and BMI
(r=0.403, p,0.001). However, testosterone levels and hirsutism
were not significantly correlated with either biallelic mean or with
X_wt_biallelic mean in the pooled cohort of case.
Discussion
Given the variation in the CAG repeat length of the androgen
receptor (AR) gene and its inverse effect on the receptor activity,
the alleles with short CAG repeat length are expected to result in
amplified androgen receptor activity, resulting in a state of
hyperandrogenism. Thus, we hypothesized that the shorter alleles
would be more frequent and preferentially more active among the
PCOS women than the controls. To the best of our knowledge,
this is the first study of its kind on a large cohort of Indian women
to examine the association of AR polymorphism with PCOS. Our
study revealed a range of 8–31 CAG repeats in the AR gene of
South Indian PCOS women and the controls. However, neither
the distribution of biallelic mean values nor the mean repeat sizes
were found significantly different between the PCOS cases and
controls. These results were concurrent to the observations of
some previous studies which did not find significant difference in
the mean values of CAG repeat sizes between PCOS cases and
controls [3,9–14]. However, there have been other studies which
yielded divergent and contradictory results; while Xita et al [5]
and Shah et al [4] found shorter alleles to be more frequent among
the PCOS cases than controls, Hickey et al [6] found longer alleles
to be significantly higher in frequency in the PCOS women than
controls. This inconsistent nature of association could be in part
accounted for by the variation in the CAG repeat number in
different populations and ethnic groups as observed by Edwards
et al. [15]. Our study did not reveal any association of CAG alleles,
shorter or longer, with PCOS; the distribution of the cases and
controls appear to be highly homogeneous across the spectrum of
CAG alleles, with odds ratio close to 1 and effect size zero. Based on
expected effects as presented in a previous study and given our
sample size the minimum effect size expected would 0.14 to be able
Table 3. Distribution (%) of PCOS cases and controls according to the qualitative categories of CAG repeats in Hindus and
Muslims.
(i)Hindus (ii)Muslims (iii)Hindu Vs Muslim
Repeat size Cases (N=158) Controls (N=218) Cases (N=81) Controls (N=61) Hindu Cases (N=158) Muslim Cases (N=81)
,19 48.1 47.2 48.1 52.4 48.1 48.1
19 7.6 9.6 12.3 11.4 7.6 12.3
.19 44.3 43.1 39.5 36.1 44.3 39.5
x2=0.477, df=2, p=0.78; x2=0.26, df=2, p=0.88; x2=1.6, df=2, p=0.44.
doi:10.1371/journal.pone.0012401.t003
Figure 2. Distribution of CAG biallelic mean among Lean and Obese PCOS cases.
doi:10.1371/journal.pone.0012401.g002
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study can be regarded as sufficiently powered to replicate the
previous association between CAG repeats and PCOS.
Since AR gene is located on X chromosome, the epigenetic
phenomenon of X chromosome inactivation leading to preferen-
tial activation of either the shorter or the longer allele may explain
the differential androgen receptor activity resulting in the pheno-
typic or clinical heterogeneity in PCOS, chiefly the androgenic
features. XCI analysis has been previously done in both PCOS
and non-PCOS cases with hyperandrogenic features. Calvo et al.
[16] found no significant difference in the pattern of X inactiva-
tion between women with hyperandrogenic hirsutism/idiopathic
hirsutism and controls. Subsequently, Shah et al [4] demonstrated
preferential inactivation of the longer CAG repeat alleles resulting
in expression of the smaller alleles that predictably increase the
androgen sensitivity. However, XCI analysis revealed random
pattern of X-inactivation of the relatively larger proportion of our
Indian samples and sub-samples. Nevertheless, concurrent to the
functional hypothesis, analysis of samples with non-random XCI
revealed that shorter alleles were preferentially more activated
among the PCOS cases than controls, although the relative
proportion of the activated alleles were not significantly different
between them (OR=1.443, p=0.33). This trend is consistent with
Shah et al [4] observation which suggests that increased intrinsic
androgenic activity associated with short AR alleles may have a
role in the pathogenesis of PCOS-related hyperandrogenism.
Hyperandrogenism, which is ascertained biochemically by
assessing the testosterone levels, and clinically by hirsutism using
the Ferriman-Gallwey score, was also taken as a parameter for
analyzing its association with CAG repeat numbers. We did not
Figure 3. Qualitative distribution of CAG biallelic mean among Lean and Obese PCOS cases. (a) for the three categories,i.e, ,18, 18–20
and .20, (b) for extreme CAG categories (,18 and .20) vs the middle range (18–20).
doi:10.1371/journal.pone.0012401.g003
Figure 4. Relative frequency of extreme and middle range of CAG repeats among the obese PCOS/lean PCOS and controls.
doi:10.1371/journal.pone.0012401.g004
CAG Repeats in PCOS Women
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12401observe any significant association between testosterone levels and
CAG repeat length which is in contrast to some of the previous
studies [3,5,6,13,17]. Consistent with the functional hypothesis,
although there is a trend of shorter CAG alleles showing lower
levels of testosterone than those with longer CAG alleles in the
PCOS women, it is not statistically significant unlike in case of the
previous studies [3,6,13]. Given the relatively large sample size,
this trend cannot be therefore considered as suggesting a relatively
greater role of excessive androgen action (implying receptor
activity) in PCOS than expected from hyperandrogenemia alone.
The obese PCOS cases of our study exhibited contrasting trend in
comparison to the lean cases, in that the shorter CAG repeat
length is associated with a high testosterone value, albeit
statistically not significant, supporting the hypothesis that
increased androgen activity in women has a stimulatory effect
on ovarian androgen production [17].
The pattern of body fat distribution can regulate androgen
production and metabolism to a significant extent [18]. Both
production rates and metabolic clearance rates of androgens are
equally increased in obesity. A condition of relative hyperandro-
genism in women are associated with abdominal obesity and all
the features of the metabolic syndrome, including insulin
resistance and compensatory hyperinsulinemia, low high-density
lipoprotein(HDL) cholesterol, increased triglycerides, and elevated
arterial blood pressure [18] that are commonly present in a PCOS
phenotype. Thus, we also examined the association of hyperan-
drogenic features in obese and lean PCOS cases separately vis-a `-
vis the CAG repeat numbers. When CAG repeat distribution
analysis was carried out among the lean and obese PCOS cases,
there was a significant difference between them (Fig.3a) whereby
the lean PCOS cases had significantly higher frequency of biallelic
mean in the middle range of 18–20 than the obese cases.
Subsequent logistic regression analysis yielded significant odds
ratio with a high statistical power of 92.8% suggesting that the
PCOS women with CAG biallelic mean range of ,18 and .20
are at a much higher risk to develop obesity and associated
metabolic complications. However, there seemed to be no epige-
netic influence over this heterogeneity, since majority of the cases
followed random XCI pattern. Apart from this, we also found
a significant positive correlation (r=0.403, p,0.001) between
hirsutism and BMI within the PCOS cases. Among the hirsute
cases, the proportion of obese PCOS women is significantly
(p=0.02) higher (77%) than the lean PCOS women (23%). This
could be explained by the increase in the metabolic clearance rate
of androgen, particularly in obese women which finally leads to
augmented hyperandrogenic features like hirsutism.
To sum up, we found homogeneity in CAG allele distribution
profile of the cases and controls, hence CAG repeat polymor-
phism, by itself, cannot be considered as a useful discriminator
between the PCOS cases and controls. Further, in spite of the lack
of evidence for a major epigenetic effect, we observed a trend of
preferential activation of the shorter allele among the PCOS cases
with non random XCI pattern. On the other hand, the significant
heterogeneity in the CAG biallelic mean between the obese and
lean PCOS cases can explain the differential receptor activity
among them, which may also probably explain the manifestation
of hyperandrogenic features in such cases. Thus, the lean PCOS
women, who have a significantly higher frequency of the middle
range CAG repeats, would possibly be conferred with a moderate
receptor activity as compared to the obese PCOS cases. In the
latter group, the lower or higher CAG repeat numbers of the
polymorphic spectrum would therefore lead to an increased or
diminished receptor activity, respectively, both of which are
expected to result in a hyperandrogenic state. We may further add
that in case of the lean PCOS group the androgen receptor CAG
repeats may not play a very instrumental role in manifestation of
the hyperandrogenic features, while in the obese PCOS group this
microsatellite variation may account for the hyperandrogenicity
to a larger extent. XCI analysis among both these groups also
revealed the same pattern as observed in the entire cohort
implying that the epigenetic effect may not have any major effect
on the androgen metabolism and receptor activity among Indian
PCOS women. Overall, our results rule out the possibility of
suggesting CAG repeat polymorphism as a prognostic marker for
PCOS. Especially given that ours is one of the largest samples so
far studied and from a relatively more homogenous population
Table 4. Odds ratio for the CAG allele categories (,18 or .20) VS (18–20) in the entire case cohort versus controls taking age and
BMI as covariates.
CAG Allele category Covariates B S.E. x2 Df p-value OR 95% C.I.
Lower Upper
BMI 20.24 0.03 60.9 1 0.00 0.78 0.73 0.83
Age 0.06 0.02 5.8 1 0.02 1.06 1.01 1.11
(,18 or .20) vs (18–20) 0.39 0.23 2.9 1 0.08 1.48 0.95 2.34
doi:10.1371/journal.pone.0012401.t004
Table 5. Odds ratio for the CAG allele categories (,18 or .20) VS (18–20) in the case cohort (for lean versus obese PCOS cases)
taking age as covariate.
CAG Allele category Covariates B S.E. x2 Df p-value OR 95% C.I.
Lower Upper
Age 0.06 0.04 2.83 1 0.092 1.06 0.98 1.14
(,18 or .20) vs (18–20) 1.11 0.34 10.82 1 0.001 3.04 1.56 5.88
doi:10.1371/journal.pone.0012401.t005
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in our sample, we may repose fair degree of confidence in the
reliability of our results. Nonetheless, our study is the first of its
kind from this region and therefore further replicative studies are
required among other ethnic groups, encompassing the geograph-
ic heterogeneity of India before reaching any unequivocal
conclusions on the precise role of androgen receptor CAG repeat
polymorphism in the manifestation of this immensely heteroge-
neous PCOS phenotype in the populations of this region.
Materials and Methods
Study Population
As part of the larger project ‘‘Identification of susceptibility
genes for Polycystic Ovary Syndrome among South-Indian
women’’, undertaken by us at the Indian Statistical Institute, a
total of 549 women consisting of 250 PCOS cases (aged 14–40
years) and 299 controls (aged 14–47 years) were recruited for the
study. Patients were enrolled from the Gynecology clinic of the
Osmania General Hospital, Hyderabad, as well as from an
infertility clinic (Anu Test Tube Baby Centre, Hyderabad), as per
the Rotterdam criteria, 2003 [19], which stipulates having any two
of the following three conditions to qualify for the inclusion: (i)
presence of clinical and/or biochemical signs of hyperandrogen-
ism, (ii) infrequent periods with intermenstrual interval of more
than 35 days, and (iii) polycystic ovaries; an ovary with the
ultrasound appearance of more than 10 subcapsular follicles
(,10 mm in diameter) in the presence of prominent ovarian
stroma was considered polycystic. Patients with hyperprolactin-
emia, thyroid and adrenal diseases, 21-hydroxylase deficiency, and
androgen-secreting tumours were excluded. The weight and
height of the 170 PCOS cases and 238 control subjects were
recorded. Hirsutism, defined as a Ferriman-Gallwey score of more
than 5 [3], could be recorded for 219 of the 250 PCOS cases.
Androgen parameters, testosterone (T) and DHEA-S, were
recorded for 174 cases. Normal controls with no history of
treatment for fertility, and with normal menstrual cycles every 25–
32 days were recruited from the family planning centre of the
Osmania hospital and from the general population. Intravenous
blood samples (,5 ml) were collected from both the patients and
controls after obtaining their informed written consent. The study
protocol was approved by the Indian Statistical Institute Review
Committee for Protection of Research Risks to Humans.
DNA extraction, amplification and Genescan analysis
DNA was extracted from the peripheral blood samples of the
patients and control using the phenol-chloroform method [20].
The CAG repeats were genotyped using a PCR-based assay.
Genomic DNA was amplified by PCR using fluorescently labeled
primers that flank the CAG repeats [21]. The forward primer was
labeled at the 59end with the dye 6FAM. Amplification was carried
out in a GeneAmp9700 thermal cycler (Applied Biosystems, Foster
City, CA) as previously described [21]. The amplified products
were separated on a denaturing polyacrylamide gel using an ABI
3730 genetic analyzer (Applied Biosystems, Foster City, CA). The
fragment size was estimated by comparison with the internal size
standard GS-LIZ500.
X-Chromosome inactivation (XCI) analysis
X inactivation analysis was carried out using the protocol given
by Hickey et al [6]. For the 471 heterozygous subjects, 100 ng of
DNA were either digested with 1U of HpaII or incubated in
digestion buffer alone at 37uC overnight, followed by incubation at
95uC for 5 min to denature the enzyme. Next, 1 ml of digested and
mock-digested products were amplified using PCR primers given
above and peak areas of both the alleles were determined using
an ABI 3730 genetic analyzer and Genemapper (version 3.7,
Applied Biosysytems). All samples were analysed in duplicate in
digested and nondigested conditions. The accuracy of the results
obtained through Genescan has also been verified through direct
sequencing.
X inactivation (relative methylation of each allele) was
quantified as previously described by Hickey et al. [6], comparing
the ratio to which each allele contributed to the total peak area
between digested and undigested samples. The X-Inactivation
percentages are expressed in terms of degree of inactivation of the
longer allele. Nonrandom X inactivation is defined as more than
60% inactivation of either allele; skewed X inactivation is defined
as more than 80% inactivation of either allele.Following X-
Inactivation analysis, we calculated X-weighted biallelic means as
per the protocol given by Hickey et al. [6], whereby each allele in a
genotypic pair is multiplied by its percent activation, and the two
adjusted repeat values are added together.
Statistical Analysis
All the statistical analyses were performed with the help of SPSS
statistical software (version 15.0, SPSS Inc, Chicago, IL, USA) and
Minitab (version 15). For power calculation, G*Power Software
(version 3.1.0) was used.
Figure 5. X-inactivation patterns in PCOS cases and controls.
doi:10.1371/journal.pone.0012401.g005
Figure 6. Distribution of CAG alleles with 60–100% activity
among women with non-random X-Inactivation pattern.
doi:10.1371/journal.pone.0012401.g006
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